Aptamers: Therapeutics, Technologies, And Services Market – The Rising Realm Amongst Stakeholders in Pursuit of Alternative Therapies to Antibodies Therapies

The aptamers market size is estimated to be worth $451 million in 2024 and is expected to reach $12,782 million by 2035, growing at CAGR of 36% during the forecast period, till 2035.

Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD). It has been reported that more than 15 million people in the US suffer from AMD alone with 200,000 cases annually across North America.  This indicates a high unmet need of patients thus, paving a way for aptamer-based solutions due to their advantages over traditional antibody-based therapies. This has led to rapid developments in the domain which can be attributed to various factors, such as number in the number of clinical trials, increased awareness about advantages offered by aptamers as compared to antibodies, rise in the investment in the pharmaceutical research and development, along with rise in prevalence of chronic and rare diseases have contributed to the increase in the demand for aptamers-based therapeutics and diagnostic solutions.  Aptamers are developed through the SELEX process and over the years these have become primary tools for aptamer synthesis.

Over the past three decades, since the invention of SELEX by Larry Gold and Jack William in the 1990, the technology has seen several modifications to streamline and standardized aptamer-isolation process. These modifications substantially enhance efficiency / optimization to yield best possible aptamer or reduce the duration of the process. Other noteworthy developments in modifications of aptamers, include the addition of functional units of non-nucleic origin and nucleotide modifications, which further improves aptamer performance.

Steps involved in the SELEX process:

·         Library Generation: Oligonucleotide library is created containing single-stranded nucleic acids having random sequences flanked by binding sites.

·         Binding and Separation: Target molecule is incubated along with the oligonucleotide library allowing for nucleic acids to bind to them resulting in the formation of aptamers. The remaining unbound nucleic acids are filtered out of the solution and through the process of elution the bound nucleic acid is separated from the target.

·         Amplification: The nucleic acids separated through the process of elution are then used to create a new library using the Polymerase Chain Reaction (PCR), this provides a new library that can be utilized for new round of SELEX thus, improving the quality of aptamers synthesized

Advantages Of Aptamers

For many years, researchers have been raising and modifying antibodies to detect specific circulating proteins and develop targeted therapeutic agents.  While antibodies are highly effective for a wide range of applications, there are unique aptamer advantages that can overcome some difficult scientific challenges.

·         Targets small molecules: Flexibility of aptamers offer wider applications as they can be developed against molecules as small as 60 Daltons this means aptamers can target molecules that are ten times smaller than antibody targets. Currently, aptamers for small molecule drugs, peptides, dyes and viral particles have been developed successfully.

·         Pursue toxic and non-immunogenic targets: Aptamer development process does not involve animals or living cells thus, making it possible to select aptamers for toxic compounds such as zootoxins and pathogenic bacteria. Additionally, aptamers do not require immune response and binding of tertiary aptamer structures to target molecules.

·         Penetrate tissues and cells: Due to their small size (30-80 nucleotides), they have enhanced ability to penetrate tissues thus, allowing them to reach specific targets efficiently. Some aptamers are able to enter cells without external assistance.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.                   

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:

Roots Analysis

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com

Website: https://www.rootsanalysis.com/